Transforming Retinal Disease Management with Novel Therapies - Episode 13

Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

Published on: 
, , , ,

Experts discuss challenges in integrating gene therapy and port delivery systems early in treating common retinal diseases while emphasizing historical challenges and safety considerations.


Experts discuss the challenges and considerations associated with incorporating novel therapies like gene therapy or port delivery systems into the early treatment regimens for common retinal diseases. Seenu Hariprasad acknowledges the high bar set for future therapies due to the safety and effectiveness of currently available treatments like aflibercept 8 mg and faricimab. He suggests that a combination of tyrosine kinase inhibitors (TKIs) and gene therapy could be a powerful approach, providing a baseline therapy that can be titrated with anti-VEGF agents. David Brown, MD emphasizes the historical challenges faced with TKIs, particularly issues related to pharmacology. He raises concerns about the potential for gene therapy to cause inflammation and highlights the safety of current treatments. Diana Do, MD expresses the challenge of incorporating gene therapy or other novel therapies early when effective and safe clinic-based options are available. She suggests that these novel therapies may be more suitable for patients with high-frequency treatment needs and without additional risk factors.

This summary was AI-generated and edited for clarity.